Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Work In Process (2018 - 2024)

IGC Pharma (IGC) has disclosed Work In Process for 7 consecutive years, with $2000.0 as the latest value for Q3 2024.

  • Quarterly Work In Process fell 81.82% to $2000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $2000.0 through Sep 2024, down 81.82% year-over-year, with the annual reading at $18000.0 for FY2023, 96.92% down from the prior year.
  • Work In Process for Q3 2024 was $2000.0 at IGC Pharma, down from $36000.0 in the prior quarter.
  • The five-year high for Work In Process was $3.9 million in Q3 2020, with the low at $2000.0 in Q3 2024.
  • Average Work In Process over 5 years is $1.7 million, with a median of $2.2 million recorded in 2020.
  • The sharpest move saw Work In Process soared 1397.18% in 2020, then plummeted 96.92% in 2023.
  • Over 5 years, Work In Process stood at $2.2 million in 2020, then increased by 0.41% to $2.2 million in 2021, then tumbled by 71.56% to $628000.0 in 2022, then plummeted by 98.25% to $11000.0 in 2023, then crashed by 81.82% to $2000.0 in 2024.
  • According to Business Quant data, Work In Process over the past three periods came in at $2000.0, $36000.0, and $11000.0 for Q3 2024, Q2 2024, and Q3 2023 respectively.